Laurus Labs Ltd share price logo

Laurus Labs Ltd Share Price (LAURUSLABS)


Get free price alerts. Set up your Free investment account to get Live Prices. >
Q1 '23 Results
News and Events

Overview of Laurus Labs Ltd

Key events for Laurus Labs Ltd

  • Multiple Players Receive Tentative Approval for Dolutegravir 50mg Tablets - 15 Sep, 2023

    Laurus Labs Ltd is one of the eight players that have received tentative approval from the USFDA to manufacture and market Dolutegravir 50mg tablets, used in treating HIV-1 infection.

  • Laurus Labs Acquires Stake in Laurus Bio; Stock Downgraded - 12 Sep, 2023

    Laurus Labs acquires a majority stake in Laurus Bio through secondary purchase. However, Kotak Institutional Equities downgrades the stock to 'Sell' due to slow performance of ARV segment.

  • Sell Call on Laurus Labs - 16 Aug, 2023

    Analyst advises to short Laurus Labs stock with a target of Rs 370 and stop loss at Rs 390 due to sustained selling pressure. Shares up over 8% in the last month.

  • Laurus Labs Reports Fall in Quarterly Profit - 14 Aug, 2023

    Laurus Labs Ltd reported a decline in quarterly profit and revenue due to weak demand in its API business, resulting in core profit margins sinking to a 19-quarter low.

  • Analysts Provide Buy/Sell Recommendations for GAIL and Laurus Labs - 09 Aug, 2023

    Kunal Bothra recommends buy/sell on GAIL and Laurus Labs, while Nooresh Merani suggests the same for GAIL and Federal Bank in today's trading session.

  • Laurus Labs Looks Attractive for Long-Term Investment - 07 Aug, 2023

    According to market experts, Laurus Labs is an attractive long-term investment due to the high number of molecules in Phase 3 and a good size of opportunity. Newland has also performed well.

  • Laurus Labs Forms Bullish Structure, P/E Ratio at 23.70 Times - 04 Aug, 2023

    Laurus Labs Ltd's stock has formed a bullish structure with higher top higher bottom formation and an A-B-C pattern breakout with volume confirmation. Additionally, the company's P/E ratio stands at 23.70 times.

  • Traders Bet on Wide Trading Range for Laurus Labs - 02 Aug, 2023

    Traders are betting on a wide trading range of 30% for Laurus Labs due to its struggle to perform this year and company problems. The range for the August series is between 300-400.

  • Laurus Labs Shares Surge After Motilal Oswal Report - 31 Jul, 2023

    Shares of Laurus Labs surged over 6% after Motilal Oswal's research report highlighted the company's lower-than-expected earnings for Q1FY24 but reiterated a BUY rating on the stock with a price target of INR410.

  • Retail Investors Hold Majority Stake in Laurus Labs - 29 Jul, 2023

    Around 35% of Laurus Labs is owned by retail investors, giving them a significant say in management and business strategy. Insiders who own 32% came under pressure after market cap dropped to ₹182b last week.

  • Laurus Labs Reports Dismal Q1 Results - 28 Jul, 2023

    Laurus Labs Ltd's Q1 FY24 results show an 88.8% plunge in consolidated net profit and 23.2% slide in revenues. Brokerages have a bleak outlook.

  • Laurus Labs' Q1 Net Profit Falls 90% - 27 Jul, 2023

    Laurus Labs Ltd's Q1 net profit fell 90% YoY to Rs 25 crore, missing analysts' estimates. Shares may be impacted.

  • Laurus Labs Reports Strong Q1 Results and Plans to Expand Manufacturing Capacity - 13 Jul, 2023

    Indian pharmaceutical company Laurus Labs beat market expectations with a 32% YoY revenue increase in Q1, driven by growth in Generics API and Synthesis business units. The company plans to expand manufacturing capacity to meet growing demand.

  • Laurus Labs Ltd stock has potential upside of up to 47% - 11 Jul, 2023

    Laurus Labs is a pharmaceutical company that develops and manufactures APIs for various therapeutic areas. The stock has seen an improvement in score and has potential upside of up to 47%.

  • Laurus Labs Ltd's Debt Management Receives Positive Review - 06 Jul, 2023

    Laurus Labs Limited has a low net debt to EBITDA ratio of only 1.2, and its EBIT covers its interest expense a whopping 10.9 times over. The company is managing its debt quite well.

  • Laurus Labs partners with IIT Kanpur for gene therapy assets - 19 Jun, 2023

    Laurus Labs partners with IIT Kanpur to bring novel gene therapy assets to market, strengthening its presence in the CGT space and funding clinical trials and product launches in emerging markets.

Analyst Rating for Laurus Labs Ltd stock

based on 10 analysts


Based on 10 analysts offering long term price targets for Laurus Labs Ltd. An average target of ₹346.2

Source: S&P Global Market Intelligence

Laurus Labs Ltd share Performance

  • ₹391.75
    downward going graph



    Day's Volatility:2.33%



    downward going graph
  • ₹278.85
    downward going graph



    52 Weeks Volatility:64.40%



    downward going graph
1 Month Return0.28 %
3 Month Return10.76 %
1 Year Return-22.83 %
Previous Close₹390.90
Market Cap₹21,298.26Cr

Laurus Labs Ltd Company Information

Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in the production of generic active pharmaceutical ingredients (APIs) in high-growth therapeutic areas like antiretrovirals (ARVs), Hepatitis C, and Oncology. The company operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh, and has invested significantly in their RD and manufacturing infrastructure, having launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, NATCO Pharma, Strides Shasun, among others. It has 34 owned patents plus 152 pending patent applications in various countries. It is increasingly focused on their integrated generics finished dosage forms FDFs business, having acquired of Sriam Labs and Richcore Lifesciences in the recent years. During 2020, it launched Hydroxychloroquine, initiated TLD supplies for the Global Fund tender, and bargained partnerships with various private and public organizations. On 2022, it infused capital in Laurus Generics Inc . and infused around Rs 46 crore to acquire a stake in Immunoadoptive Cell Therapy Private Limited, among other expansions and operations.

Share Price: ₹395.40 per share as on 29 Sep, 2023 04:01 PM
Market Capitalisation: ₹21,298.26Cr as of today
Revenue: ₹1,382.61Cr as on March 2023 (Q1 23)
Net Profit: ₹102.98Cr as on March 2023 (Q1 23)
Listing date: 19 Dec, 2016
Chairperson Name: M Venu Gopala Rao
OrganisationLaurus Labs Ltd
E-voting on sharesClick here to vote

Fundamentals of Laurus Labs Ltd

Insights on Laurus Labs Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    FII Holding Up

    Foreign Institutions have increased holdings from 22.42% to 22.52% in Jun 2023 quarter

  • imgNO EFFECT

    Against Peers

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 121.5% return, outperforming this stock by 87.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    Promoters holdings remained unchanged at 27.20% of holdings in Jun 2023 quarter

  • imgNO EFFECT

    Against Peers

    In the last 1 year, Dr Reddys Laboratories Ltd has given 26.4% return, outperforming this stock by 49.2%


    Price Dip

    In the last 1 year, LAURUSLABS stock has moved down by -22.8%


    Profit Down

    Netprofit is down for the last 4 quarters, 251.28 Cr → 102.98 Cr (in ₹), with an average decrease of 23.1% per quarter


    Retail Holding Down

    Retail Investor have decreased holdings from 40.64% to 39.93% in Jun 2023 quarter


    MF Holding Down

    Mutual Funds have decreased holdings from 5.40% to 5.14% in Jun 2023 quarter


    Revenue Fall

    Revenue is down for the last 3 quarters, 1.57K Cr → 1.38K Cr (in ₹), with an average decrease of 6.3% per quarter

Laurus Labs Ltd share Valuation

Laurus Labs Ltd in the last 5 years

  • Overview

  • Trends

Lowest (16.96x)

March 28, 2023

Today (37.77x)

September 29, 2023

Industry (48.71x)

September 29, 2023

Highest (193.71x)

September 18, 2020


Mutual Fund Holdings

Funds Holdings
Mirae Asset Midcap Fund Direct GrowthMirae Asset Midcap Fund Direct Growth1.17%
PGIM India Midcap Opportunities Fund Direct GrowthPGIM India Midcap Opportunities Fund Direct Growth1.08%
Franklin India Prima Fund Direct GrowthFranklin India Prima Fund Direct Growth1.11%
Kotak Emerging Equity Scheme Direct GrowthKotak Emerging Equity Scheme Direct Growth0.28%
Sundaram Mid Cap - Direct Plan - Growth OptionSundaram Mid Cap - Direct Plan - Growth Option0.98%

Laurus Labs Ltd Shareholding Pattern

InvestorsHoldings %Prev. 2 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Technicals of Laurus Labs Ltd share

News & Events of Laurus Labs Ltd

Frequently Asked Questions

Laurus Labs Ltd (LAURUSLABS) share price today is ₹395.4

  • Today’s highest price of Laurus Labs Ltd is ₹400.95.
  • Today’s lowest price of Laurus Labs Ltd is ₹391.75.

Today’s traded volume of Laurus Labs Ltd(LAURUSLABS) is 18.47L.

Today’s market capitalisation of Laurus Labs Ltd(LAURUSLABS) is ₹21298.26Cr.

Laurus Labs Ltd(LAURUSLABSPrice
52 Week High
52 Week Low

Laurus Labs Ltd(LAURUSLABS) share price is ₹395.4. It is down -25.89% from its 52 Week High price of ₹533.5

Laurus Labs Ltd(LAURUSLABS) share price is ₹395.4. It is up 41.80% from its 52 Week Low price of ₹278.85

Laurus Labs Ltd(LAURUSLABSReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns